Nanocarriers as treatment modalities for hypertension

References

• ACE 2 Modulator [Online]. Available at: http://www.apeiron-biologics.com [last accessed 14 Apr 2016]
   Google Scholar
• Adis Insight [Online]. Available at: http://adisinsight.springer.com/drugs/800003008 [last accessed 12 Apr 2016]
   Google Scholar
• Akbarzadeh A, Samiei M, Davaran S. (2012). Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett 7:144
   PubMed Web of Science ®Google Scholar
• Ambrisentan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) [Online]. (2016). Available at: www.reuters.com [last accessed 11 Apr 2016]
   Google Scholar
• Andersen K. (2013). Aldosterone synthase inhibition in hypertension. Curr Hypertens Rep 15:484–8
   PubMed Web of Science ®Google Scholar
• Ansari KA, Pagar KP, Anwar S, et al. (2014). Design and optimization of self-microemulsifying drug delivery system (SMEDDS) of felodipine for chronotherapeutic application. Braz J Pharm Sci. 50:203–12
   Web of Science ®Google Scholar
• Antal A, Kubovcikova M, Zavisova V, et al. (2015). Magnetic poly(D,L-lactide) nanoparticles loaded with aliskiren: a promising tool for hypertension treatment. J Magn Magn Mater 380:280–4
   Web of Science ®Google Scholar
• Anuradha K, Kumar MS. (2014). Development of Lacidipine loaded nanostructured lipid carriers (NLCs) for bioavailability enhancement. Int J Pharm Med Res 2:50–7
   Google Scholar
• Aronow WS. (2012). Treatment of systemic hypertension. Am J Cardiovasc Dis 2:160–70
   PubMedGoogle Scholar
• Arora A, Shafiq N, Jain S, et al. (2015). Development of sustained release “NanoFDC (Fixed Dose Combination)” for hypertension – an experimental study. PLoS One 10:e0128208
   PubMed Web of Science ®Google Scholar
• Basalious EB, Shawky N, Badr-Eldin SM. (2010). SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: development and optimization. Int J Pharm 391:203–11
   PubMed Web of Science ®Google Scholar
• Beg S, Sharma G, Thanki K, et al. (2015). Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: systematic development, in vitro, ex vivo and in vivo evaluation. Int J Pharm 493:466–82
   PubMed Web of Science ®Google Scholar
• Beg S, Swain S, Singh HP, et al. (2012). Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers. AAPS PharmSciTech 13:1416–27
   PubMed Web of Science ®Google Scholar
• Beloqui A, Solinis MA, Rodriguez-Gascon A, et al. (2016). Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine 12:143–61
   PubMed Web of Science ®Google Scholar
• Beveridge T, Gratwohl A, Michot F, et al. (1981). Cyclosporine: pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogenic bone-marrow grafts. Curr Ther Res 30:5–18
   Web of Science ®Google Scholar
• BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen [Online]. Available at: http://www.biolinerx.com [last accessed 14 Apr 2016]
   Google Scholar
• Bruno BJ, Miller GD, Lim CS. (2013). Basics and recent advances in peptide and protein drug delivery. Ther Deliv 4:1443–67
   PubMedGoogle Scholar
• Carey RM, Padia RH. (2008). Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab 19:84–7
   PubMed Web of Science ®Google Scholar
• Cautreels W. (2007). Building the next Solvay pharmaceuticals [Online]. Available at: http://www.solvay.com/en/binaries/20070926_Pharma-135279.pdf [last accessed 10 Apr 2016]
   Google Scholar
• Chadha R, Bhandari S, Darpan K, et al. (2013). Exploring lecithin/chitosan nanoparticles of ramipril for improved antihypertensive efficacy. J Nanopharm Drug Deliv 1:173–81
   Google Scholar
• Chhabra G, Chuttani K, Mishra AK, et al. (2011). Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. Drug Dev Ind Pharm 37:907–16
   PubMed Web of Science ®Google Scholar
• Connect 2 Capital [Online]. Available at: https://www.b2match.eu/connect2capital [last accessed 10 Apr 2016]
   Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. (2012). PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161:505–22
   PubMed Web of Science ®Google Scholar
• Desai PP, Date AA, Patravale VB. (2012). Overcoming poor oral bioavailability using nanoparticle formulations – opportunities and limitations. Drug Discov Today Technol 9:e87–95
   Google Scholar
• Dudhipala N, Veerabrahma K. (2015). Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design. Drug Dev Ind Pharm 41:1968–77
   PubMed Web of Science ®Google Scholar
• ElKasabgy NA, Elsayed I, Elshafeey AH. (2014). Design of lipotomes as a novel dual functioning nanocarrier for bioavailability enhancement of lacidipine: in-vitro and in-vivo characterization. Int J Pharm 472:369–79
   PubMed Web of Science ®Google Scholar
• El-Kattan A, Varma M. 2012. Oral absorption, intestinal metabolism and human oral bioavailability. In James P, ed. Topics on drug metabolism. Rijeka, Croatia: In Tech. Available at: http://www.intechopen.com/books/topics-on-drug-metabolism
   Google Scholar
• Ernsberger P, Haxhiu MA, Graff LM, et al. (1994). A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist. Cardiovasc Drugs Ther 8:27–41
   PubMed Web of Science ®Google Scholar
• FDA Approves Edarbi (azilsartan medoxomil) for the Treatment of Hypertension [Online]. Available at: http://www.takeda.com/news/2011/20110226_3833.html [last accessed 10 Apr 2016]
   Google Scholar
• Ghosh S, Roy T. (2014). Nanoparticulate drug-delivery systems: lymphatic uptake and its gastrointestinal applications. JAPS 4:123–30
   Google Scholar
• Gilead and Navitas Announce Agreement for Cicletanine for the Treatment of Pulmonary Arterial Hypertension [Online]. Available at: www.gilead.com [last accessed 14 Apr 2016]
   Google Scholar
• Gorain B, Choudhury H, Kundu A, et al. (2013). Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats. Colloids Surf B Biointerfaces 115:286–94
   PubMed Web of Science ®Google Scholar
• Gursoy RN, Benita S. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 58:173–82
   PubMed Web of Science ®Google Scholar
• Ha E-S, Choo G-H, Baek I-H, et al. (2015). Dissolution and bioavailability of lercanidipine-hydroxypropylmethyl cellulose nanoparticles with surfactant. Int J Biol Macromolec 72:218–22
   PubMed Web of Science ®Google Scholar
• Han L, Tang C, Yin C. (2014). Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy. Biomaterials 35:4589–600
   PubMed Web of Science ®Google Scholar
• Hauss DJ. (2007). Oral lipid-based formulations. Adv Drug Deliv Rev 59:667–76
   PubMed Web of Science ®Google Scholar
• Havanoor SM, Manjunath K, Bhagawati ST, et al. (2014). Isradipine loaded solid lipid nanoparticles for better treatment of hypertension – preparation, characterization and in vivo evaluation. Int J Biopharm 5:218–24
   Google Scholar
• Head GA, Mayorov DN. (2006). Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc Hematol Agents Med Chem 4:17–32
   PubMedGoogle Scholar
• Hetal T, Bindesh P, Sneha T. (2010). A review on techniques for oral bioavailability enhancement of drugs. Int J Pharmaceu Sci Rev Res 4:203–23
   Google Scholar
• Iglarz M, Binkert C, Morrison K, et al. (2008). Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharm of Exp Ther 327:736–45
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Watanabe Y, Takayama K, et al. (2000). Effect of hydroxypropylmethylcellulose (HPMC) on the release profiles and bioavailability of a poorly water-soluble drug from tablets prepared using macrogol and HPMC. Int J Pharm 202:173–8
   PubMed Web of Science ®Google Scholar
• Jang D-J, Jeong EJ, Lee H-M, et al. (2006). Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion. Eur J Pharm Sci 28:405–11
   PubMed Web of Science ®Google Scholar
• Khan S, Khan S, Baboots S, Ali J. (2015). Immunosuppressive drug therapy-biopharmaceutical challenges and remedies. Expert Opin Drug Deliv 12:1333–49
   PubMed Web of Science ®Google Scholar
• Koziolek M, Grimm M, Becker D, et al. (2015). Investigation of pH and temperature profiles in the GI tract of fasted human subjects using the Intellicap(®) system. J Pharm Sci 104:2855–63
   PubMed Web of Science ®Google Scholar
• Kim YI, Fluckiger L, Hoffman M, et al. (1997). The antihypertensive effect of orally administered nifedipine–loaded nanoparticles in spontaneously hypertensive rats. Br J Pharmacol 120:399–404
   PubMed Web of Science ®Google Scholar
• Knipe JM, Strong LE, Peppas NA. (2016). Enzyme- and pH-responsive microencapsulated nanogels for oral delivery of siRNA to induce TNF-α knockdown in the intestine. Biomacromolecules 17:788–97
   PubMed Web of Science ®Google Scholar
• Koenig O, Walker T, Perle N, et al. (2013). New aspects of gene-silencing for the treatment of cardiovascular diseases. Pharmaceuticals (Basel) 6:881–914
   PubMedGoogle Scholar
• Kuentz M. (2012). Lipid-based formulations for oral delivery of lipophilic drugs. Drug Discov Today Technol 9:e97–104
   Google Scholar
• Kumar VV, Chandrasekar D, Ramakrishna S, et al. (2007). Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm 335:167–75
   PubMed Web of Science ®Google Scholar
• Labato MA. (2008). Antihypertensives. Chapter 159. 840–845
   Google Scholar
• Li P, Dai Y-N, Zhang JP, et al. (2008). Chitosan-alginate nanoparticles as a novel drug delivery system for nifedipine. Int J Biomed Sci 4:2228
   Google Scholar
• McLendon JM, Joshi SR, Sparks J, et al. (2015). Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. J Control Release 210:67–75
   PubMed Web of Science ®Google Scholar
• McMurray JJV. (2015). Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail 17:242–7
   PubMed Web of Science ®Google Scholar
• Morrell NW, Archer SL, DeFelice A, et al. (2013). Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ 3:226–44
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50:161–77
   PubMed Web of Science ®Google Scholar
• Muller RH, Radtke M, Wissing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54:S131–55
   PubMed Web of Science ®Google Scholar
• Nepolean R, Narayanan N, Subramaniyan N, et al. (2012). Colon targeted methacrylic acid copolymeric nanoparticles for improved oral bioavailability of nisoldipine. IJBPR 962–7
   Google Scholar
• Neves AR, Queiroz JF, Lima SAC, et al. (2016). Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: relevance for oral drug delivery. J Colloid Interface Sci 463:258–65
   PubMed Web of Science ®Google Scholar
• New macitentan (Opsumit) efficacy data in pulmonary arterial hypertension from SERAPHIN study presented at European Society of Cardiology Congress [Online]. (2013). Available at: http://www.reuters.com/article/idUSnHUGdgtq+70+ONE20130902 [last accessed 11 Apr 2016]
   Google Scholar
• Niaz T, Shabbir S, Manzoor S, et al. (2016). Antihypertensive nano-ceuticales based on chitosan biopolymer: physico-chemical evaluation and release kinetics. Carbohyd Polym 142:268–74
   PubMed Web of Science ®Google Scholar
• NicOx’ naproxcinod shows highly significant reduction in daytime blood pressure versus naproxen. New analysis of the 104 ABPM study presented at the American Heart Association [Online]. (2008). Available at: http://www.nicox.com [last accessed 14 Apr 2016]
   Google Scholar
• Nolte A, Schneider M, Walker T, et al. 2011. Gene-silencing for treatment of cardiovascular diseases. In Eberli D, ed. Regenerative medicine and tissue engineering - cells and biomaterials. Rijeka, Croatia: INTECH 2011
   Google Scholar
• Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization [Online]. Available at: https://www.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-lcz696-now-called-entrestotm-approved-fda [last accessed 10 Apr 2016]
   Google Scholar
• Nunes T, Rocha JF, Vaz-da-Silva, et al. (2010). Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs in R & D 10:225–42
   Google Scholar
• O'Driscoll CM, Griffin BT. (2008). Biopharmaceutical challenges associated with drugs with low aqueous solubility—The potential impact of lipid-based formulations. Adv Drug Deliv Rev 60:617–24
   PubMed Web of Science ®Google Scholar
• ohara-ch [Online]. Available at: www.ohara-ch.co.jp [last accessed 10 Apr 2016]
   Google Scholar
• Oparil S, Schmieder RE. (2015). New approaches in the treatment of hypertension. Circ Res 116:1074–95
   PubMed Web of Science ®Google Scholar
• Palatin Technologies, Inc [Online]. Available at: http://www.palatin.com/programs/heart-failure [last accessed 11 Apr 2016]
   Google Scholar
• Paulis L, Unger T. (2010). Novel therapeutic targets for hypertension. Nat Rev Cardiol 7:431–41
   PubMed Web of Science ®Google Scholar
• Paulis L, Rajkovicova R, Simko F. (2015). New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?. Curr Hypertens Rep 17:42
   Web of Science ®Google Scholar
• Pridgen EM, Alexis F, Farokhzad OC. (2014). Polymeric nanoparticle technologies for oral drug delivery. Clin Gastroenterol Hepatol 12:1605–10
   PubMed Web of Science ®Google Scholar
• Ranpise NS, Korabu SS, Ghodake VN. (2014). Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces 116:81–7
   PubMed Web of Science ®Google Scholar
• Selvamuthukumar S, Velmurugan R. (2012). Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis 11:159
   PubMed Web of Science ®Google Scholar
• Shafiq S, Shakeel F, Talegaonkar S, et al. (2007). Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 66:227–43
   PubMed Web of Science ®Google Scholar
• Shah MK, Madan P, Lin S. (2014a). Preparation, in vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration. Pharm Dev Technol 19:475–85
   PubMed Web of Science ®Google Scholar
• Shah U, Joshi G, Sawant K. (2014b). Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design. Mater Sci Eng C Mater Biol Appl 35:153–63
   PubMed Web of Science ®Google Scholar
• Sharma N, Bansal M, Visht, et al. (2010). Nanoemulsion: a new concept of delivery system. Chron Young Sci 1:2–6
   Google Scholar
• Singh B, Singh R, Bandyopadhyay S, et al. (2013). Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol. Colloids Surf B Biointerfaces 101:465–74
   PubMed Web of Science ®Google Scholar
• Townsend R, Bittar N, Rosen J, et al. (2011). Blood pressure effects of naproxcinod in hypertensive patients. J Clin Hypertens (Greenwich) 13:376–84
   PubMed Web of Science ®Google Scholar
• Tran PH-L, Tran TT-D, Lee B-J. (2013). Enhanced solubility and modified release of poorly water-soluble drugs via self-assembled gelatin–oleic acid nanoparticles. Int J Pharm 455:235–40
   PubMed Web of Science ®Google Scholar
• Tripathi KD. 2004. Essentials of medical pharmacology. 6th ed. India: Jaypee Brothers Medical Publishers
   Google Scholar
• Turner JR. (2009). Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9:799–809
   PubMed Web of Science ®Google Scholar
• Vitae Reports Positive Clinical Data in Chronic Kidney Disease Program at the American Diabetes Association’s 71st Scientific Sessions [Online]. Available at: http://ir.vitaepharma.com/phoenix.zhtml?c=219654&p=irol-newsArticle&ID=1963893 [last accessed 10 Apr 2016]
   Google Scholar
• Voruganti S, Yamsani SK, Ravula SK, et al. (2010). Effect of pomegranate juice on intestinal transport and pharmacokinetics of nitrendipine in rats. Phytother Res 26:1240–5
   Web of Science ®Google Scholar
• WHO. (2013). A global brief on hypertension [Online]. Available at: http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/ [last accessed 3 Feb 2016]
   Google Scholar
• Zabihi F, Yang M, Leng Y, et al. (2015). PLGA–HPMC nanoparticles prepared by a modified supercritical anti-solvent technique for the controlled release of insulin. J Supercrit Fluid 99:15–22
   Web of Science ®Google Scholar
• Zhang Z, Gao F, Bu H, et al. (2012). Solid lipid nanoparticles loading candesartan cilexitil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomedicine 8:740–7
   PubMed Web of Science ®Google Scholar
• Zhong JC, Basu R, Guo R, et al. (2010). Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Am Heart Assoc 122:717–28
   Google Scholar
• Zhuang Y, Sun L, Zhang Y, Liu G. (2012). Antihypertensive effect of long term oral administration of jellyfish (Rhopilema esculentum) collagen peptides on renovascular hypertension. Mar Drugs 10:417–26
   PubMed Web of Science ®Google Scholar
• Zisaki A, Miskovic L, Hatzimanikatis V. (2015). Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches. Curr Pharm Des 21:806–22
   PubMed Web of Science ®Google Scholar